An American thoracic society official research statement: Future directions in lung fibrosis research

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 7, 2016, Pages 792-800

  White, Eric S ^a   Borok, Zea ^a   Brown, Kevin K ^a   Eickelberg, Oliver ^a   Guenther, Andreas ^a   Gisli Jenkins, R ^a   Kolb, Martin ^a   Martinez, Fernando J ^a   Roman, Jesse ^a   Sime, Patricia ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biomedical research; Consensus; Patient advocacy; Patient care; Pulmonary fibrosis

Indexed keywords

ANIMAL MODEL; ARTICLE; CELLS BY BODY ANATOMY; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; DISEASE MODEL; EX VIVO STUDY; FUNDING; GOVERNMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG FIBROSIS; MEDICAL RESEARCH; MEDICAL SOCIETY; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PATIENT ADVOCACY; PRECLINICAL STUDY; PRIORITY JOURNAL; CONSENSUS; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH; INTERNATIONAL COOPERATION; NEEDS ASSESSMENT; ORGANIZATION AND MANAGEMENT; PROCEDURES; PROGRAM DEVELOPMENT; STANDARDS; UNITED STATES; RESEARCH PRIORITY; SYSTEMATIC REVIEW;

BIOMEDICAL RESEARCH; CONSENSUS; FUND RAISING; GLOBAL HEALTH; HUMANS; INTERNATIONAL COOPERATION; NEEDS ASSESSMENT; PATIENT ADVOCACY; PROGRAM DEVELOPMENT; PULMONARY FIBROSIS; RESEARCH SUPPORT AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84981321016     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201602-0254ST     Document Type: Article

References (28)

1. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-2082.
2. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370: 2083-2092.
3. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, et al. Future directions in idiopathic pulmonary fibrosis research: An NHLBI workshop report. Am J Respir Crit Care Med 2014;189:214-222.
4. Roman J, Brown KK, Olson A, Corcoran BM, Williams KJ; ATS Comparative Biology of Lung Fibrosis Working Group. An official American thoracic society workshop report: comparative pathobiology of fibrosing lung disorders in humans and domestic animals. Ann Am Thorac Soc 2013;10:S224-S229.
5. White ES, Brown KK, Collard HR, Conoscenti CS, Cosgrove GP, Flaherty KR, Leff JA, Martinez FJ, Roman J, Rose D, et al. Open-access biorepository for idiopathic pulmonary fibrosis: The way forward. Ann Am Thorac Soc 2014;11:1171-1175.
6. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 2011;4:165-178.
7. Hubbard R, Johnston I, Coultas DB, Britton J. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996; 51:711-716.
8. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/ JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
9. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L152-L160.
10. Pauluhn J, Baumann M, Hirth-Dietrich C, Rosenbruch M. Rat model of lung fibrosis: comparison of functional, biochemical, and histopathological changes 4 months after single irradiation of the right hemithorax. Toxicology 2001;161:153-163.
11. Verkman AS. From the farm to the lab: The pig as a new model of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol 2008; 295:L238-L239.
12. Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012; 186:314-324.
13. Culver DA, Newman LS, Kavuru MS. Gene-environment interactions in sarcoidosis: challenge and opportunity. Clin Dermatol 2007;25: 267-275.
14. Thannickal VJ, Zhou Y, Gaggar A, Duncan SR. Fibrosis: ultimate and proximate causes. J Clin Invest 2014;124:4673-4677.
15. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-816.
16. Olson AL, Swigris JJ. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med 2012;33:41-50.
17. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB. The rising incidence of idiopathic pulmonary fibrosis in the U. K. Thorax 2011;66:462-467.
18. Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012;15:829-835.
19. Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, Raghu G. Health care utilization and costs of idiopathic pulmonary fibrosis in U. S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 2015;12:981-987.
20. Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB. The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest 2013;143:1078-1084.
21. Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE Jr, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, et al.; IPFnet investigators. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: Analysis of a pooled cohort from three clinical trials. Lancet Respir Med 2015;3: 388-396.
22. Pittman JE, Cutting G, Davis SD, Ferkol T, Boucher R. Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc 2014;11:S161-S168.
23. The IPFnet strategy: creating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:527-528.
24. Raghu G; IPFnet. Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials. Chest 2009;136:330-333.
25. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012;21:355-361.
26. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163: 1256-1276.
27. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30:2-5.
28. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013 62: D34-D41.